Inhibition of MET signaling is currently achievable in NSCLC patients using the MET/ALK/ROS tyrosine-kinase inhibitor (TKI) Crizotinib or selective MET-TKIs (Capmatinib, Savolitinib, Tepotinib, Cabozantinib), or MET or HGF monoclonal antibodies (mAbs), as well as MET or HGF antibody–drug conjugates [2,3,4,5]. The gene discussed is HGF; the disease is non-small cell lung carcinoma.